FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
In the largest collaborative study so far, an international team of researchers, including scientists from VIB and Antwerp University identified novel causes for severe childhood epilepsies. The researchers analyzed the genetic information of 356 patients and their parents. In their analysis, the research teams looked for genes that had acquired new mutations in the children with severe epilepsies when compared to the DNA of the parents. In total, they identified 429 new mutations and in 12% of children, these mutations were considered unequivocally causative for the patient's epilepsy. In addition to several known genes for childhood epilepsies, the research team found strong evidence for additional novel genes, many of which are involved in the function of the synapse, the main structure in the nervous system that allows for communication between neurons. read more
Esperite (Euronext.: ESP), the European leader in stem cells cryopreservation now entering the fields of predictive medicine and translational regenerative medicine R&D,, implements its own proprietary new technology for clinical grade production of autologous mesenchymal and stromal stem cells in its business unit The Cell Factory. read more
Galapagos NV (Euronext: GLPG) announced today a share capital increase arising from warrant exercises. read more
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx® for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014. read more
Novosanis, a spin-off company from the University of Antwerp, has received the James Dyson Award for its VAX-ID device. The device allows for injection in the dermal layer of the skin, which provides a better immune response because of the presence of dendritic cells in the skin. read more
ALZPROTECT, a biopharmaceutical company involved in the development of new therapeutic solutions in the neurodegenerative diseases area, announces that the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM, French health authority) has authorized the Company to begin the Phase I trial for AZP2006. read more
arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has completed enrolment of a first cohort of 15 patients with CD70-positive solid tumors into an open-label Phase 1b expansion trial with ARGX-110, a novel anti-CD70 therapeutic antibody. Recruitment of a second cohort of 15 patients with CD70-positive hematological malignancies is ongoing. The primary objective of the expansion trial is to select one or more indications to take forward into further clinical trials. read more
Esperite NV (Euronext.: ESP, 'Esperite' or 'the Group'), the European leader in stem cells cryopreservation, now entering the fields of predictive medicine and translational regenerative medicine R&D, announces the appointment of Dr. Thomas Rio Frio as Genomics Manager of its business unit Genoma. read more
Galapagos NV (Euronext: GLPG) announced today that more than 100 patients have completed the six month Darwin 1 and 2 studies with GLPG0634 in rheumatoid arthritis and entered Darwin 3, the long term extension study. With the support of their treating physicians, over 90% of the patients who participated in Darwin 1 and Darwin 2 have chosen to participate in Darwin 3, in which all patients will receive long term treatment with Galapagos' highly selective JAK1 inhibitor. read more
Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and NYSE Euronext Paris: CARD), leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has received the recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 clinical trial according to the original protocol. The recommendation is based on a planned analysis performed on all patient safety data available as per mid-August 2014. read more